Immune Design Prices Public Offering of Common Stock
April 15, 2015 18:50 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 15, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) today announced the pricing of an underwritten public offering of 3,000,000 shares of its common...
Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents
March 31, 2015 16:10 ET
|
Immune Design Corp.
SEATTLE and SAN FRANCISCO, March 31, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, reported today that analyses of data from three...
Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
March 31, 2015 16:08 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today reported financial results and provided a...
Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent
March 26, 2015 08:00 ET
|
Immune Design Corp.
Prime-Boost in vivo T cell active immunotherapy
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company...
Immune Design Announces Upcoming Financial Results and Immuno-oncology Conference Presentation
March 23, 2015 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report...
Immune Design Appoints Lewis W. Coleman to Board of Directors
March 19, 2015 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of...
Immune Design to Present at Upcoming Investment Conferences
February 24, 2015 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D.,...
Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent
February 11, 2015 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced the start of a Phase 1 clinical trial of G100 in...
Immune Design to Present at the 2015 Leerink Global Healthcare Conference
February 05, 2015 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that Carlos Paya, M.D., Ph.D., President...
Immune Design to Present at the 33rd Annual J.P. Morgan Healthcare Conference
January 07, 2015 16:02 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that Carlos Paya, M.D., Ph.D.,...